Jigar Mistry of Buoyant Capital favors healthcare, materials, chemicals, and banking sectors, preferring large-cap private banks over PSU banks. He remains positive on both generic and CDMO pharma segments, dismissing tariff concerns. Mistry believes valuations are elevated, especially for narrative-driven stocks lacking earnings, advocating for a focus on fundamentals over market flows.
Pankaj Tibrewal sees stronger top-line growth driving India’s next earnings cycle
Indian companies are poised to navigate input cost pressures and sustain growth, with the upcoming earnings season expected to be the next market trigger. Experts
June 30, 2026